Serum osteopontin and CD44 levels in lymphoreticular malignancies in children

Bratislava Medical Journal

Volumn 113, Issue 9, 2012, Pages 534-538

  Elli, M ^a   Dagdemir, A ^a   Bozkurt, C ^b   Pinarli, F G ^a   Duzgun, A ^a   Ozmen, Z C ^a   Ertem, U ^b   Acar, S ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

Author keywords

CD44; Children; Leukemia; Lymphoma; Osteopontin

Indexed keywords

HERMES ANTIGEN; OSTEOPONTIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD; CHILD; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; ANTIGENS, CD44; CHILD; CHILD, PRESCHOOL; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; OSTEOPONTIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84871765382     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2012_120     Document Type: Article

References (44)

1. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16: 885-893.
2. Prince CW, Oosawa T, Butler WT et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987; 262: 2900-2907.
3. Higashibata Y, Sakuma T, Kawahata H et al. Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta and mammary gland: an analysis of transgenic mice. J Bone Miner Res 2004; 19: 78-88.
4. Takahashi F, Takahashi K, Shimizu K et al. Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung 2004; 182: 173-185.
5. Rodrigues LR, Teixerira JA, Schmitt F et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1-11.
6. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-241.
7. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-196.
8. Stamenkovic I, Aminot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56: 1057-1062.
9. Guo YJ, Liu G, Wang X et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994; 54: 422-426.
10. Furger KA, Menon RK, Tuck AB et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-632.
11. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-1881.
12. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-5215.
13. Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994; 9: 2321-2326.
14. Tuck AB, Arsenault DM, O'Malley FP et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18: 4237-4246.
15. Lecrone V, Li W, Devoll RE et al. Calcium signals in prostate cancer cells: specific activation by bone- matrix proteins. Cell Calcium 2000; 27: 35-42.
16. Thalmann GN, Sikes RA, Devoll RE et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999; 5: 2271-2277.
17. Hirama M, Takahashi F, Takahaski K et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198: 107-117.
18. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162: 127-133.
19. Ristamaki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood 1994; 84: 238-243.
20. Le QT, Chen E, Salim A et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507-1514.
21. Cho EY, Choi Y, Chae SW et al. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 2006; 56: 62-70.
22. Watanabe O, Kinoshita J, Shimizu T et al. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 2005; 24: 75-82.
23. Tuck AB, O'Malley FP, Singhal H et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121: 578-584.
24. Zhang J, Takahashi K, Takahashi F et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171: 215-222.
25. Agrawal D, Chen T, Irby R et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
26. Ue T, Yokozaki H, Kitadai Y et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79: 127-132.
27. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
28. Gotoh M, Sakamoto M, Kanetaka K et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52: 19-24.
29. Fedarko NS, Jain A, Karadag A et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066.
30. Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-611.
31. Agrawal D, Chen T, Irby R et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
32. Ang C, Chambers AF, Tuck AB et al. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 2005; 96: 803-805.
33. Koopman G, Heider KH, Horst E et al. Activated human lymphocytes and aggressive non-Hodgkińs lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993; 177: 897-904.
34. Pals ST, Horst E, Ossekoppele GJ et al. Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood 1989; 73: 885-888.
35. Jalkanen S, Joensuu H, Soderstrom KO, Klemi P. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 1991: 87: 1835-1840.
36. Tacyildiz N, Cavdar AO, Yavuz G et al. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival. Pediatr Int 2001; 43: 354-360.
37. Liu J, and Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol 2006; 3: 359-365.
38. Legras S, Günthert U, Stauder R et al. A strong expression of CD44- 6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998; 9: 3401-3413.
39. Magyarosy E, Sebestyen A, Timar J. Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. Anticancer Res 2001; 21: 819-823.
40. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY, Zhou J. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008; 13: 1155-1165.
41. Samanna V, Wei H, Ego-Osuala D, Chellaiah MA: Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res 2006; 312: 2214-2230.
42. Desai B, Rogers MJ, Chellaiah MA. Mechanism of osteopontin and CD44 as a metastatic principle in prostate cells. Mol Cancer 2007; 6: 18-33.
43. Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, Denhardt DT. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005; 22: 663-673.
44. Marroquin CE, Downey L, Guo H, Kuo PC Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunol Lett 2004; 95: 109-112